biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Dec 13 (Reuters)

<< Previous

Bullboard Posts

Next >>

Post by fuzzyjron Dec 13, 2022 10:39am

263 Views

Post# 35168354

Dec 13 (Reuters)

Reuters - Updated 10 minutes ago

Dec 13 (Reuters) - Midatech Pharma PLC:

* MIDATECH PHARMA PLC - ACQUISITION OF BIOASIS TECHNOLOGIES INC

* MIDATECH PHARMA PLC - PROPOSED DEAL FOR CONSIDERATION OF, IN AGGREGATE, APPROXIMATELY C$7.4 MILLION

* MIDATECH PHARMA PLC - EQUITY RAISE OF US$10.0 MILLION

* MIDATECH PHARMA: DEAL TO BE SATISFIED BY ISSUE OF 75.9M NEW SHARES OF 0.1P EACH IN CO CAPITAL AT EXCHANGE RATIO OF 0.9556 SHARES FOR EACH BIOASIS SHARE Source text for Eikon: Further company coverage:

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record